Current efforts on generation of optimal immune responses against HIV through mucosal immunisations

Drugs in R and D

Volumn 7, Issue 5, 2006, Pages 267-288

  Vajdy, Michael ^a,b  

^a Novartis Vaccines and Diagnostics   (United States)

^b MS X 600A   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIV 1 PEPTIDE VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIVE VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPOTENTIATION; LYMPH NODE; MUCOSAL IMMUNITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VIRUS TRANSMISSION;

AIDS VACCINES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; MALE;

EID: 33747892494     PISSN: 11745886     EISSN: 11745886     Source Type: Journal    
DOI: 10.2165/00126839-200607050-00001     Document Type: Review

References (212)

1. Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 2006; 24 (19): 4062-81. Epub 2006 Feb 28
2. Haase AT, Henry K, Zupancic M, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996 Nov 8; 274 (5289): 985-9
3. Spira AI, Marx PA, Patterson BK, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996 Jan 1; 183 (1): 215-25
4. Heise C, Vogel P, Miller CJ, et al. Distribution of SIV infection in the gastrointestinal tract of rhesus macaques at early and terminal stages of AIDS. J Med Primatol 1993 Feb; 22 (2-3): 187-93
5. Mazzoli S, Trabattoni D, Lo CS, et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 1997 Nov; 3 (11): 1250-7
6. Lehner T, Wang Y, Cranage M, et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996 Jul; 2 (7): 767-75
7. Bomsel M, Heyman M, Hocini H, et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998 Aug; 9 (2): 277-87
8. McGhee JR, Lamm ME, Strober W. Mucosal immune responses. In: Ogra PL, Mestecky J, Lamm ME, et al., editors. Mucosal immunology. San Diego (CA): Academic Press, 1999: 485-506
9. Gallichan WS, Rosenthal KL. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 1995; 13 (16): 1589-95
10. Staats HF, Montgomery SP, Palker TJ. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res Hum Retroviruses 1997; 13 (11): 945-52
11. Wu HY, Abdu S, Stinson D, et al. Generation of female genital tract antibody responses by local or central (Common) mucosal immunization. Infect Immun 2000; 68 (10): 5539-45
12. Johansson EL, Rask C, Fredriksson M, et al. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun 1998 Feb; 66 (2): 514-20
13. Di Tommaso A, Saletti G, Pizza M, et al. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun 1996; 64 (3): 974-9
14. Bergquist C, Johansson EL, Lagergard T, et al. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 1997; 65 (7): 2676-84
15. van Ginkel FW, Jackson RJ, Yuki Y, et al. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000 Nov 1; 165 (9): 4778-82
16. Duverger A, Jackson RJ, van Ginkel FW, et al. Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol 2006 Feb 1; 176 (3): 1776-83
17. Eriksson AM, Schon KM, Lycke NY. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J Immunol 2004 Sep 1; 173 (5): 3310-9
18. Lycke N. From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance. Immunol Lett 2005 Mar 15; 97 (2): 193-8
19. Boyaka PN, Tafaro A, Fischer R, et al. Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity. Curr Pharm Des 2003; 9 (24): 1965-72
20. Fujimura Y. Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans. Virchows Arch 2000 Jun; 436 (6): 560-6
21. Pope M. Mucosal dendritic cells and immunodeficiency viruses. J Infect Dis 1999 May; 179 Suppl. 3: S427-30
22. Moore KL, Dalley AF. Clinically oriented anatomy. 4th ed. Baltimore (MD): Lippincott Williams & Wilkins, 1999
23. Neutra MR, Frey A, Kraehenbuhl JP. Epithelial M cells: gateways for mucosal infection and immunization. Cell 1996 Aug 9; 86 (3): 345-8
24. Kutteh WH, Moldoveanu Z, Mestecky J. Mucosal immunity in the female reproductive tract: correlation of immunoglobulins, cytokines, and reproductive hormones in human cervical mucus around the time of ovulation. AIDS Res Hum Retroviruses 1998; 14 Suppl. 1: S51-5
25. Crowley-Nowick PA, Bell MC, Brockwell R, et al. Rectal immunization for induction of specific antibody in the genital tract of women. J Clin Immunol 1997 Sep; 17 (5): 370-9
26. Mestecky J, Fultz PN. Mucosal immune system of the human genital tract. J Infect Dis 1999 May; 179 Suppl. 3: S470-4
27. Vajdy M, Veazey RS, Knight HK, et al. Differential effects of simian immunodeficiency virus infection on immune inductive and effector sites in the rectal mucosa of rhesus macaques. Am J Pathol 2000 Aug; 157 (2): 485-95
28. Pavli P, Maxwell L, van de Pol E, et al. Distribution of human colonic dendritic cells and macrophages: functional implications. Adv Exp Med Biol 1995; 378: 121-3
29. Yeaman GR, White HD, Howell A, et al. The mucosal immune system in the human female reproductive tract: potential insights into the heterosexual transmission of HIV. AIDS Res Hum Retroviruses 1998 Apr; 14 Suppl. 1: S57-62
30. Johansson EL, Rudin A, Wassen L, et al. Distribution of lymphocytes and adhesion molecules in human cervix and vagina. Immunology 1999 Feb; 96 (2): 272-7
31. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000; 74 (13): 6087-95
32. Lohman BL, Miller CJ, McChesney MB. Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques. J Immunol 1995 Dec 15; 155 (12): 5855-60
33. McChesney MB, Collins JR, Miller CJ. Mucosal phenotype of antiviral cytotoxic T lymphocytes in the vaginal mucosa of SIV-infected rhesus macaques. AIDS Res Hum Retroviruses 1998 Apr; 14 Suppl. 1: S63-S6
34. Challacombe SJ, Rahman D, O'Hagan DT. Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine 1997 Feb; 15 (2): 169-75
35. Ugozzoli M, O'Hagan DT, Ott GS. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunology 1998; 93 (4): 563-71
36. Parr MB, Parr EL. Immunohistochemical localization of immunoglobulins A, G and M in the mouse female genital tract. J Reprod Fertil 1985; 74 (2): 361-70
37. Thaparr MA, Parr EL, Bozzola JJ, et al. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM). Vaccine 1991; 9 (2): 129-33
38. O'Hagan DT, Rafferty D, McKeating JA, et al. Vaginal immunization of rats with a synthetic peptide from human immunodeficiency virus envelope glycoprotein. J Gen Virol 1992; 73 (Pt 8): 2141-5
39. O'Hagan DT, Rafferty D, Wharton S, et al. Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. Vaccine 1993; 11 (6): 660-4
40. Vajdy M, Gardner J, Neidleman J, et al. Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles. J Infect Dis 2001; 184 (12): 1613-6
41. Wira CR, Richardson J, Prabhala R. Endocrine regulation of mucosal immunity: effect of sex hormones and cytokines on the afferent and efferent arms of the immune system in the female reproductive tract. In: Ogra PL, Lamm ME, Mcghee JR, et al., editors. Handbook of mucosal immunology. San Diego (CA): Academic Press, 1994: 705-18
42. Kaul R, Trabattoni D, Bwayo JJ, et al. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 1999 Jan 14; 13 (1): 23-9
43. Devito C, Hinkula J, Kaul R, et al. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr 2002; 30 (4): 413-20
44. Vajdy M, Veazey RS, Knight HK, et al. Differential effects of simian immunodeficiency virus infection on immune inductive and effector sites in the rectal mucosa of rhesus macaques. Am J Pathol 2000 Aug; 157 (2): 485-95
45. Sissons JG, Oldstone MB. Killing of virus-infected cells by cytotoxic lymphocytes. J Infect Dis 1980 Jul; 142 (1): 114-9
46. Kohl S. Role of antibody-dependent cellular cytotoxicity in defense against herpes simplex virus infections. Rev Infect Dis 1991 Jan-Feb; 13 (1): 108-14
47. Kohl S, Strynadka NC, Hodges RS, et al. Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B. J Clin Invest 1990 Jul; 86 (1): 273-8
48. Sawyer LA, Katzenstein DA, Hendry RM, et al. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res Hum Retroviruses 1990 Mar; 6 (3): 341-56
49. Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J 1996 Feb; 10 (2): 258-66
50. Brenner BG, Gryllis C, Wainberg MA. Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases. J Leukoc Biol 1991; 50: 628-40
51. Tyler DS, Lyerly HK, Weinhold KJ. Anti-HIV-1 ADCC. AIDS Res Hum Retroviruses 1989 Dec; 5 (6): 557-63
52. Kozlowski PA, Cu-Uvin S, Neutra MR, et al. Mucosal vaccination strategies for women. J Infect Dis 1999 May; 179 Suppl. 3: S493-S8
53. Kozlowski PA, Cu-Uvin S, Neutra MR, et al. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997 Apr; 65 (4): 1387-94
54. Eriksson K, Quiding-Jarbrink M, Osek J, et al. Specific antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. Infect Immun 1998 Dec; 66 (12): 5889-96
55. Giuliani MM, Del Giudice G, Giannelli V, et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 1998 Apr 6; 187: 1123-32
56. Asanuma H, Aizawa C, Kurata T, et al. IgA antibody-forming cell responses in the nasal-associated lymphoid tissue of mice vaccinated by intranasal, intravenous and/or subcutaneous administration. Vaccine 1998 Aug; 16 (13): 1257-62
57. Lowell GH, Kaminski RW, VanCott TC, et al. Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG. J Infect Dis 1997 Feb; 175 (2): 292-301
58. Gupta S, Janani R, Bin Q, et al. Characterization of HIV-gag-specific IFNg-expressing cells following protective mucosal immunization with alphavirus replicon particles. J Virol 2005; 79 (11): 7135-45
59. Imaoka K, Miller CJ, Kubota M, et al. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J Immunol 1998 Dec 1; 161 (11): 5952-8
60. Moldoveanu Z, Clements ML, Prince SJ, et al. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 1995 Aug; 13 (11): 1006-12
61. Enose Y, Ui M, Miyake A, et al. Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. Virology 2002 Jul 5; 298 (2): 306-16
62. Keren DF, McDonald RA, Carey JL. Combined parenteral and oral immunization results in an enhanced mucosal immunoglobulin A response to Shigella flexneri. Infect Immun 1988 Apr; 56 (4): 910-5
63. Koster FT, Pierce NF. Parenteral immunization causes antigen-specific cell-mediated suppression of an intestinal IgA response. J Immunol 1983 Jul; 131 (1): 115-9
64. Bruhl P, Kerschbaum A, Eibl MM, et al. An experimental prime-boost regimen leading to HIV type 1-specific mucosal and systemic immunity in BALB/c mice. AIDS Res Hum Retroviruses 1998 Mar 20; 14 (5): 401-7
65. Zolla-Pazner S, Lubeck M, Xu S, et al. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J Virol 1998 Feb; 72 (2): 1052-9
66. Vajdy M, Singh M, Kazzaz J, et al. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intra-nasal and parenteral immunizations. AIDS Res Hum Retroviruses 2004; 20 (11): 1269-81
67. Vajdy M, Singh M, Ugozzoli M, et al. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology 2003 Sep; 110 (1): 86-94
68. Herremans TM, Reimerink JH, Buisman AM, et al. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 1999 Apr 15; 162 (8): 5011-8
69. Cyster JG. Homing of antibody secreting cells. Immunol Rev 2003 Aug; 194: 48-60
70. Kunkel EJ, Butcher EC. Plasma-cell homing. Nat Rev Immunol 2003 Oct; 3 (10): 822-9
71. Johansson C, Ahlstedt I, Furubacka S, et al. Differential expression of chemokine receptors on human IgA+ and IgG+ B cells. Clin Exp Immunol 2005 Aug; 141 (2): 279-87
72. Williams IR. Chemokine receptors and leukocyte trafficking in the mucosal immune system. Immunol Res 2004; 29 (1-3): 283-92
73. King NJ, Parr EL, Parr MB. Migration of lymphoid cells from vaginal epithelium to iliac lymph nodes in relation to vaginal infection by herpes simplex virus type 2. J Immunol 1998 Feb 1; 160 (3): 1173-80
74. Andrew DP, Ruffing N, Kim CH, et al. C-C chemokine receptor 4 expression defines a major subset of circulating nonintestinal memory T cells of both Th1 and Th2 potential. J Immunol 2001 Jan 1; 166 (1): 103-11
75. Campbell DJ, Butcher EC. Rapid acquisition of tissue-specific homing phenotypes by CD4 (+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med 2002 Jan 7; 195 (1): 135-41
76. Krieg C, Maier R, Meyerhans A. Gut-homing (alpha (4)beta (7) (+)) Th1 memory responses after inactivated poliovirus immunization in poliovirus orally pre-immunized donors. J Gen Virol 2004 Jun; 85 (Pt 6): 1571-9
77. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001 Mar 21; 19 (17-19): 2688-91
78. Mora M, Veggi D, Santini L, et al. Reverse vaccinology: identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Drug Discov Today 2003 May 15; 8 (10): 459-64
79. Rappuoli R, Pizza M, Scarlato V, et al. Reverse vaccinology. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Curr Opin Microbiol 2000 Oct; 3 (5): 445-50
80. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000 Mar 10; 287 (5459): 1816-20
81. Clements JD, Finkelstein RA. Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures. Infect Immun 1979; 24 (3): 760-9
82. Clements JD, Yancey RJ, Finkelstein RA. Properties of homogeneous heat-labile enterotoxin from Escherichia coli. Infect Immun 1980; 29 (1): 91-7
83. Pizza M, Domenighini M, Hol W, et al. Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol Microbiol 1994; 14 (1): 51-60
84. Pizza M, Fontana MR, Giuliani MM, et al. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J Exp Med 1994; 180 (6): 2147-53
85. Partidos CD, Pizza M, Rappuoli R, et al. The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide. Immunology 1996 Dec; 89 (4): 483-7
86. SF2 p55 gag-specific cytotoxic responses through mucosal immunization. Immunology 2000; 101: 154-60
87. Ugozzoli M, Santos G, Donnelly J, et al. Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant. J Infect Dis 2001; 183 (2): 351-4
88. Staats HF, Nichols WG, Palker TJ, et al. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN (A). J Immunol 1996 Jul 1; 157 (1): 462-72
89. Holmgren J, Adamsson J, Anjuere F, et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 2005 Mar 15; 97 (2): 181-8
90. Bird AP. CpG islands as gene markers in the vertebrate nucleus. Trends Genet 1987; 3: 342-7
91. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408 (6813): 740-5
92. Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine 1999; 17 (1): 19-25
93. Broide D, Schwarze J, Tighe H, et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998; 161 (12): 7054-62
94. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 2004 Jun; 199: 227-50
95. Jiang JQ, Patrick A, Moss RB, et al. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J Virol 2005 Jan; 79 (1): 393-400
96. Dumais N, Patrick A, Moss RB, et al. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J Infect Dis 2002 Oct 15; 186 (8): 1098-105. Epub 2002 Sep 30
97. Kang SM, Guo L, Yao Q, et al. Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J Virol 2004 Sep; 78 (18): 9624-32
98. Horner AA, Datta SK, Takabayashi K, et al. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J Immunol 2001; 167 (3): 1584-91
99. Clark MA, Hirst BH, Jepson MA. Lectin-mediated mucosal delivery of drugs and microparticles. Adv Drug Deliv Rev 2000 Sep 30; 43 (2-3): 207-23
100. Manocha M, Pal PC, Chitralekha KT, et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 2005; 23 (48-49): 5599-617
101. Miyake A, Akagi T, Enose Y, et al. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques. J Med Virol 2004 Jul; 73 (3): 368-77
102. Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 1995; 12 (1): 1-99
103. Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. Nat Biotechnol 1998 Feb; 16 (2): 153-7
104. Eldridge JH, Staas JK, Meulbroek JA, et al. Biodegradable and biocompatible poly (DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 1991 Sep; 59 (9): 2978-86
105. O'Hagan DT, Rahman D, McGee JP, et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 1991 Jun; 73 (2): 239-42
106. O'Hagan DT, Jeffery H, Roberts MJ, et al. Controlled release microparticles for vaccine development. Vaccine 1991 Oct; 9 (10): 768-71
107. O'Hagan DT, Jeffery H, Davis SS. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 1993; 11 (9): 965-9
108. Maloy KJ, Donachie AM, O'Hagan DT, et al. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly (lactide-co-glycolide) microparticles. Immunology 1994 Apr; 81 (4): 661-7
109. Moore A, McGuirk P, Adams S, et al. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine 1995 Dec; 13 (18): 1741-9
110. Nixon DF, Hioe C, Chen PD, et al. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 1996 Nov; 14 (16): 1523-30
111. Randolph GJ, Inaba K, Robbiani DF, et al. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999 Dec; 11 (6): 753-61
112. Lutsiak ME, Robinson DR, Coester C, et al. Analysis of poly (D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res 2002; 19 (10): 1480-7
113. Newman KD, Elamanchili P, Kwon GS, et al. Uptake of poly (D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res 2002; 60 (3): 480-6
114. Kazzaz J, Neidleman J, Singh M, et al. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J Control Release 2000; 67 (2-3): 347-56
115. Alving CR. Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. Biochim Biophys Acta 1992 Dec 11; 1113 (3-4): 307-22
116. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol Today 1990 Mar; 11 (3): 89-97
117. VanCott TC, Kaminski RW, Mascola JR, et al. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol 1998 Feb 15; 160 (4): 2000-12
118. Ambrosch F, Wiedermann G, Jonas S, et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997 Aug; 15 (11): 1209-13
119. Sakaue G, Hiroi T, Nakagawa Y, et al. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J Immunol 2003 Jan 1; 170 (1): 495-502
120. Lian T, Bui T, Ho RJ. Formulation of HIV-envelope protein with lipid vesicles expressing ganglioside GM1 associated to cholera toxin B enhances mucosal immune responses. Vaccine 1999 Nov 12; 18 (7-8): 604-11
121. Barr IG, Sjolander A, Cox JC. ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev 1998; 32: 247-71
122. Hu KF, Lovgren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev 2001 Sep 23; 51 (1-3): 149-59
123. Lovgren-Bengtsson K, Morein B. The ISCOM™ technology. In: O'Hagan D, editor. Vaccine adjuvants: preparation methods and research protocols. Totowa (NJ): Humana Press, 2000: 239-58
124. Bradney CP, Sempowski GD, Liao HX, et al. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J Virol 2002; 76 (2): 517-24
125. Albu DI, Jones-Trower A, Woron AM, et al. Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins. J Virol 2003 May; 77 (10): 5589-97
126. Ahlers JD, Belyakov intramuscular, Berzofsky JA. Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr Mol Med 2003 May; 3 (3): 285-301
127. Akagi T, Kawamura M, Ueno M, et al. Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice. J Med Virol 2003 Feb; 69 (2): 163-72
128. Kawahara M, Matsuo K, Nakasone T, et al. Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen. Vaccine 2002 Dec 13; 21 (3-4): 158-66
129. Golding B, Eller N, Levy L, et al. Mucosal immunity in mice immunized with HIV-1 peptide conjugated to Brucella abortus. Vaccine 2002 Jan 31; 20 (9-10): 1445-50
130. Deml L, Speth C, Dierich MP, et al. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 2005 Feb; 42 (2): 259-77
131. Yao Q, Bu Z, Vzorov A, et al. Virus-like particle and DNA-based candidate AIDS vaccines. Vaccine 2003 Jan 30; 21 (7-8): 638-43
132. Yao Q. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Res Initiat Treat Action 2003 Spring; 8 (2): 20-1
133. Gronowski AM, Hilbert DM, Sheehan KC, et al. Baculovirus stimulates antiviral effects in mammalian cells. J Virol 1999 Dec; 73 (12): 9944-51
134. Donnelly JJ, Ulmer JB, Liu MA. DNA vaccines. Life Sci 1997; 60 (3): 163-72
135. Donnelly JJ, Friedman A, Martinez D, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1995; 1 (6): 583-7
136. Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282 (5388): 476-80
137. Roy MJ, Wu MS, Barr LJ, et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000; 19 (7-8): 764-78
138. Haas J, Park E, Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996; 6 (3): 315-24
139. zur Megede J, Chen MC, Doe B, et al. Increased expression and immuunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J Virol 2000 Mar; 74 (6): 2628-35
140. Andre S, Seed B, Eberle J, et al. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998 Feb; 72 (2): 1497-503
141. Uchijima M, Yoshida A, Nagata T, et al. Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium. J Immunol 1998; 161 (10): 5594-9
142. Sasaki S, Tsuji T, Asakura Y, et al. The search for a potent DNA vaccine against AIDS: the enhancement of immunogenicity by chemical and genetic adjuvants. Anticancer Res 1998; 18 (5D): 3907-16
143. Wang X, Kochetkova I, Haddad A, et al. Transgene vaccination using Ulex europaeus agglutinin I (UEA-1) for targeted mucosal immunization against HIV-1 envelope. Vaccine 2005 May 31; 23 (29): 3836-42
144. Okada E, Sasaki S, Ishii N, et al. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997 Oct 1; 159 (7): 3638-47
145. Wierzbicki A, Kiszka I, Kaneko H, et al. Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein. Vaccine 2002; 20 (9-10): 1295-307
146. Xin KQ, Lu Y, Hamajima K, et al. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clin Immunol 1999; 92 (1): 90-6
147. Wang X, Hone DM, Haddad A, et al. M cell DNA vaccination for CTL immunity to HIV. J Immunol 2003 Nov 1; 171 (9): 4717-25
148. Hamajima K, Kojima Y, Matsui K, et al. Chitin micro-particles (CMP): a useful adjuvant for inducing viral specific immunity when delivered intranasally with an HIV-DNA vaccine. Viral Immunol 2003; 16 (4): 541-7
149. Singh M, Vajdy M, Gardner J, et al. Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine 2001; 20 (3-4): 594-602
150. Yan C, Rill WL, Malli R, et al. Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres. Vaccine 1996 Aug; 14 (11): 1031-8
151. Kuper CF, Koornstra PJ, Hameleers DM, et al. The role of nasopharyngeal lymphoid tissue. Immunol Today 1992 Jun; 13 (6): 219-24
152. Alpar HO, Almeida AJ, Brown MR. Microsphere absorption by the nasal mucosa of the rat. J Drug Target 1994; 2 (2): 147-9
153. Marx PA, Compans RW, Gettie A, et al. Protection against vaginal SIV transmission with microencapsulated vaccine. Science 1993 May 28; 260 (5112): 1323-7
154. Denis-Mize KS, Dupuis M, MacKichan ML, et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther 2000; 7 (24): 2105-12
155. Singh M, Briones M, Ott G, et al. Cationic microparticles: a potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A 2000; 97 (2): 811-6
156. Sasaki S, Hamajima K, Fukushima J, et al. Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine. Infect Immun 1998; 66 (2): 823-6
157. Cleland JL, Barron L, Daugherty A, et al. Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120. J Pharm Sci 1997; 85 (12): 1350-7
158. Cannon G, Weissman D. RNA based vaccines. DNA Cell Biol 2002 Dec; 21 (12): 953-61
159. Martinon F, Krishnan S, Lenzen G, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 1993; 23 (7): 1719-22
160. Polo JM, Gardner JP, Ji Y, et al. Alphavirus DNA and particle replicons for vaccines and gene therapy. Dev Biol (Basel) 2000; 104: 181-5
161. Li HO, Zhu YF, Asakawa M, et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 2000 Jul; 74 (14): 6564-9
162. Schoen C, Kolb-Maurer A, Geginat G, et al. Bacterial delivery of functional messenger RNA to mammalian cells. Cell Microbiol 2005 May; 7 (5): 709-24
163. Michiels A, Tuyaerts S, Bonehill A, et al. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther 2005 May; 12 (9): 772-82
164. Yoshii K, Hayasaka D, Goto A, et al. Packaging the replicon RNA of the Far-Eastern subtype of tick-borne encephalitis virus into single-round infectious particles: development of a heterologous gene delivery system. Vaccine 2005 Jun 10; 23 (30): 3946-56
165. Shinya K, Fujii Y, Ito H, et al. Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine. J Virol 2004 Mar 7; 78 (6): 3083-8
166. Ahlquist P, Schwartz M, Chen J, et al. Viral and host determinants of RNA virus vector replication and expression. Vaccine 2005 Mar 7; 23 (15): 1784-7
167. Rayner JO, Dryga SA, Kamrud KI. Alphavirus vectors and vaccination. Rev Med Virol 2002 Sep-Oct; 12 (5): 279-96
168. Schlesinger S. Alphavirus vectors: development and potential therapeutic applications. Expert Opin Biol Ther 2001 Mar; 1 (2): 177-91
169. Schlesinger S, Dubensky TW. Alphavirus vectors for gene expression and vaccines. Curr Opin Biotechnol 1999 Oct; 10 (5): 434-9
170. Leitner WW, Hwang LN, deVeer MJ, et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 2003 Jan; 9 (1): 33-9
171. Caley IJ, Betts MR, Irlbeck DM, et al. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol 1997 Apr; 71 (4): 3031-8
172. Berglund P, Quesada-Rolander M, Putkonen P, et al. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses 1997 Nov 20; 13 (17): 1487-95
173. Brand D, Lemiale F, Turbica I, et al. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles. AIDS Res Hum Retroviruses 1998; 14 (15): 1369-77
174. Davis NL, West A, Reap E, et al. Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 2002 Apr-May; 53 (4-5): 209-11
175. Belyakov intramuscular, Moss B, Strober W, et al. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci U S A 1999 Apr 13; 96 (8): 4512-7
176. Hofmann-Lehmann R, Vlasak J, Williams AL, et al. Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 2003 Jan 24; 17 (2): 157-66
177. Ruprecht RM. Live attenuated AIDS viruses as vaccines: promise or peril? Immunol Rev 1999; 170: 135-49
178. Baba TW, Liska V, Khimani AH, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999; 5 (2): 194-203
179. Baba TW, Jeong YS, Pennick D, et al. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995; 267 (5205): 1820-5
180. Wyand MS, Manson K, Montefiori DC, et al. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 1999; 73 (10): 8356-63
181. Johnson RP, Lifson JD, Czajak SC, et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 1999 Jun; 73 (6): 4952-61
182. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292 (5514): 69-74
183. Gherardi MM, Najera JL, Perez-Jimenez E, et al. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J Virol 2003 Jun; 77 (12): 7048-57
184. Gherardi MM, Perez-Jimenez E, Najera JL, et al. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol 2004 May 15; 172 (10): 6209-20
185. Stevceva L, Alvarez X, Lackner AA, et al. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV (gpe) recombinant vaccine result in gag-specific CD8 (+) T-cell responses in mucosal tissues of macaques. J Virol 2002 Nov; 76 (22): 11659-76
186. Bertley FM, Kozlowski PA, Wang SW, et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol 2004 Mar 15; 172 (6): 3745-57
187. Wang SW, Bertley FM, Kozlowski PA, et al. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS. AIDS Res Hum Retroviruses 2004 Aug; 20 (8): 846-59
188. Kent SJ, Dale CJ, Ranasinghe C, et al. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpox-virus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine 2005 Oct 10; 23 (42): 5009-21
189. Makitalo B, Lundholm P, Hinkula J, et al. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J Gen Virol 2004 Aug; 85 (Pt 8): 2407-19
190. Johnson DC, McFarland EJ, Muresan P, et al. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. J Infect Dis 2005 Dec 15; 192 (12): 2129-33
191. Wright PF, Mestecky J, McElrath MJ, et al. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J Infect Dis 2004 Apr 1; 189 (7): 1221-31
192. Musey L, Ding Y, Elizaga M, et al. HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals. J Immunol 2003 Jul 15; 171 (2): 1094-101
193. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001; 106 (5): 539-49
194. Egan MA, Chong SY, Rose NF, et al. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 2004 Sep; 20 (9): 989-1004
195. Haglund K, Leiner I, Kerksiek K, et al. High-level primary CD8 (+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. J Virol 2002 Mar; 76 (6): 2730-8
196. Schmitt B. Vesicular stomatitis. Vet Clin North Am Food Anim Pract 2002 Nov; 18 (3): 453-9, vii-viii
197. Letchworth GJ, Rodriguez LL, Del C Barrera J. Vesicular stomatitis. Vet J 1999 May; 157 (3): 239-60
198. Natuk RJ, Chanda PK, Lubeck MD, et al. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model. Proc Natl Acad Sci U S A 1992 Aug 15; 89 (16): 7777-81
199. Natuk RJ, Lubeck MD, Chanda PK, et al. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res Hum Retroviruses 1993 May; 9 (5): 395-404
200. Lubeck MD, Natuk RJ, Chengalvala M, et al. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res Hum Retroviruses 1994 Nov; 10 (11): 1443-9
201. Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 2005 Feb; 16 (2): 149-56
202. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004; 55: 355-72
203. Santra S, Seaman MS, Xu L, et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 2005 May; 79 (10): 6516-22
204. Mascola JR, Sambor A, Beaudry K, et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol 2005 Jan; 79 (2): 771-9
205. Gomez-Roman VR, Patterson LJ, Venzon D, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005 Feb 15; 174 (4): 2185-9
206. Casimiro DR, Bett AJ, Fu TM, et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 2004 Oct; 78 (20): 11434-8
207. Gomez-Roman VR, Robert-Guroff M. Adenoviruses as vectors for HIV vaccines. AIDS Rev 2003 Jul-Sep; 5 (3): 178-85
208. Shata MT, Hone DM. Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8 (+) T cells and antiviral protective immunity. J Virol 2001; 75 (20): 9665-70
209. Devico AL, Fouts TR, Shata MT, et al. Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine 2002 May 6; 20 (15): 1968-74
210. Vecino WH, Morin PM, Agha R, et al. Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV. Immunol Lett 2002 Jul 3; 82 (3): 197-204
211. Xu F, Hong M, Ulmer JB. Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella. Vaccine 2003 Jan 30; 21 (7-8): 644-8
212. International AIDS Vaccine Initiative [online]. Available from URL: http://www.iavi.org [Accessed 2006 Aug 16]